Collegium Pharmaceutical, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Collegium Pharmaceutical, Inc. payments for repurchase of common stock for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Collegium Pharmaceutical, Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Collegium Pharmaceutical, Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00.
- Collegium Pharmaceutical, Inc. payments for repurchase of common stock for the quarter ending 2025-06-30 was $25.10M.
- Collegium Pharmaceutical, Inc. payments for repurchase of common stock for fiscal 2025 was $25.10M, a 58.18% decline from fiscal 2024.
- Collegium Pharmaceutical, Inc. payments for repurchase of common stock for fiscal 2024 was $60.02M, a 19.97% decline from fiscal 2023.
- Collegium Pharmaceutical, Inc. payments for repurchase of common stock for fiscal 2023 was $75.00M, a 433.31% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. payments for repurchase of common stock for fiscal 2022 was $14.06M, a 70.62% decline from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.10M 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2025-06-30 | $25.10M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $25.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $60.02M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2023-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $75.00M 10-K · filed 2026-02-26 |
| 2022-12-31 | $7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.06M 10-K · filed 2025-02-27 |
| 2021-12-31 | $32.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $47.86M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |